PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
NYSE:MD - New York Stock Exchange, Inc. - US58502B1061 - Common Stock - Currency: USD
Taking everything into account, MD scores 5 out of 10 in our fundamental rating. MD was compared to 102 industry peers in the Health Care Providers & Services industry. MD has only an average score on both its financial health and profitability. MD is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
MD had positive earnings in the past year.
MD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
Each year in the past 5 years MD had a positive operating cash flow.
1.2 Ratios
The Return On Assets of MD (-4.13%) is worse than 64.71% of its industry peers.
MD has a Return On Equity of -10.44%. This is comparable to the rest of the industry: MD outperforms 40.20% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.08%, MD is in the better half of the industry, outperforming 78.43% of the companies in the same industry.
MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.60%.
The last Return On Invested Capital (9.08%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.13% | ||
| ROE | -10.44% | ||
| ROIC | 9.08% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
The Operating Margin of MD (10.02%) is better than 81.37% of its industry peers.
In the last couple of years the Operating Margin of MD has declined.
MD does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.02% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
MD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MD has been increased compared to 5 years ago.
MD has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 1.88 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.88, MD is in line with its industry, outperforming 44.12% of the companies in the same industry.
MD has a debt to FCF ratio of 3.15. This is a good value and a sign of high solvency as MD would need 3.15 years to pay back of all of its debts.
MD's Debt to FCF ratio of 3.15 is fine compared to the rest of the industry. MD outperforms 75.49% of its industry peers.
A Debt/Equity ratio of 0.75 indicates that MD is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.75, MD is in line with its industry, outperforming 47.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | 3.15 | ||
| Altman-Z | 1.88 |
ROIC/WACC1.1
WACC8.29%
2.3 Liquidity
MD has a Current Ratio of 1.81. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a better Current ratio (1.81) than 66.67% of its industry peers.
A Quick Ratio of 1.81 indicates that MD should not have too much problems paying its short term obligations.
MD's Quick ratio of 1.81 is fine compared to the rest of the industry. MD outperforms 68.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.71%, which is quite impressive.
MD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.01% yearly.
Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -1.13% in the last year.
Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 2.49% on average per year.
EPS 1Y (TTM)31.71%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%65%
Revenue 1Y (TTM)-1.13%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.42%
3.2 Future
The Earnings Per Share is expected to decrease by -1.96% on average over the next years.
The Revenue is expected to grow by 2.05% on average over the next years.
EPS Next Y12.58%
EPS Next 2Y8.41%
EPS Next 3Y6.79%
EPS Next 5Y-1.96%
Revenue Next Year-5.69%
Revenue Next 2Y-1.57%
Revenue Next 3Y0.53%
Revenue Next 5Y2.05%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.59, the valuation of MD can be described as reasonable.
MD's Price/Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 95.10% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.17, MD is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 7.94, the valuation of MD can be described as very cheap.
Based on the Price/Forward Earnings ratio, MD is valued cheaper than 93.14% of the companies in the same industry.
MD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.59 | ||
| Fwd PE | 7.94 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MD indicates a rather cheap valuation: MD is cheaper than 85.29% of the companies listed in the same industry.
MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 91.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.15 | ||
| EV/EBITDA | 6.45 |
4.3 Compensation for Growth
MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.68
PEG (5Y)N/A
EPS Next 2Y8.41%
EPS Next 3Y6.79%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:MD (5/29/2025, 12:25:06 PM)
13.91
+0.19 (+1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners100.19%
Inst Owner Change-2.06%
Ins Owners1.43%
Ins Owner Change0.39%
Market Cap1.20B
Analysts77.65
Price Target18.43 (32.49%)
Short Float %2.31%
Short Ratio2.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.85%
Min EPS beat(2)32.73%
Max EPS beat(2)34.96%
EPS beat(4)4
Avg EPS beat(4)22.2%
Min EPS beat(4)5.21%
Max EPS beat(4)34.96%
EPS beat(8)5
Avg EPS beat(8)6.83%
EPS beat(12)5
Avg EPS beat(12)1.12%
EPS beat(16)9
Avg EPS beat(16)4.81%
Revenue beat(2)1
Avg Revenue beat(2)-0.56%
Min Revenue beat(2)-1.44%
Max Revenue beat(2)0.31%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-3.14%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-3.01%
Revenue beat(16)3
Avg Revenue beat(16)-2.21%
PT rev (1m)-1.56%
PT rev (3m)11.45%
EPS NQ rev (1m)2.95%
EPS NQ rev (3m)4.12%
EPS NY rev (1m)5.62%
EPS NY rev (3m)6.54%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)-4.32%
Revenue NY rev (1m)1.04%
Revenue NY rev (3m)-3.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.59 | ||
| Fwd PE | 7.94 | ||
| P/S | 0.6 | ||
| P/FCF | 6.15 | ||
| P/OCF | 5.58 | ||
| P/B | 1.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.45 |
EPS(TTM)1.62
EY11.65%
EPS(NY)1.75
Fwd EY12.59%
FCF(TTM)2.26
FCFY16.26%
OCF(TTM)2.49
OCFY17.94%
SpS23
BVpS9.19
TBVpS-5.4
PEG (NY)0.68
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.13% | ||
| ROE | -10.44% | ||
| ROCE | 11.5% | ||
| ROIC | 9.08% | ||
| ROICexc | 10.41% | ||
| ROICexgc | 62.51% | ||
| OM | 10.02% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 9.83% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexcg growth 3Y26.95%
ROICexcg growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | 3.15 | ||
| Debt/EBITDA | 2.62 | ||
| Cap/Depr | 73.43% | ||
| Cap/Sales | 1.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 95.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 1.88 |
F-Score5
WACC8.29%
ROIC/WACC1.1
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.71%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%65%
EPS Next Y12.58%
EPS Next 2Y8.41%
EPS Next 3Y6.79%
EPS Next 5Y-1.96%
Revenue 1Y (TTM)-1.13%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.42%
Revenue Next Year-5.69%
Revenue Next 2Y-1.57%
Revenue Next 3Y0.53%
Revenue Next 5Y2.05%
EBIT growth 1Y30.12%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year33%
EBIT Next 3Y12.91%
EBIT Next 5YN/A
FCF growth 1Y45.08%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y31.09%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%